These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18618289)

  • 1. Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.
    Al Sawaf S; Mayatepek E; Hoffmann B
    J Inherit Metab Dis; 2008 Aug; 31(4):473-80. PubMed ID: 18618289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in MPS I and MPS II Disease Manifestations.
    Hampe CS; Yund BD; Orchard PJ; Lund TC; Wesley J; McIvor RS
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
    Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
    Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neurologic manifestations in mucopolysaccharidoses].
    Héron B
    Arch Pediatr; 2014 Jun; 21 Suppl 1():S14-21. PubMed ID: 25063379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
    Beck M
    Curr Pharm Biotechnol; 2011 Jun; 12(6):861-6. PubMed ID: 21235446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebral infarction in Hunter syndrome.
    Neely J; Carpenter J; Hsu W; Jordan L; Restrepo L
    J Clin Neurosci; 2006 Dec; 13(10):1054-7. PubMed ID: 17056260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound findings of carpal tunnel syndrome in a Hunter syndrome patient.
    Alkhachroum AM; Preston DC
    Muscle Nerve; 2016 Jan; 53(1):147-50. PubMed ID: 26479407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucopolysaccharidosis Type II and the G374sp Mutation.
    Martínez-Quintana E; Rodríguez-González F
    Mol Syndromol; 2013 Apr; 4(4):203-6. PubMed ID: 23801937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: emphasis on the cardiovascular complication and mortality cases.
    Sohn YB; Choi EW; Kim SJ; Park SW; Kim SH; Cho SY; Jeong SI; Huh J; Kang IS; Lee HJ; Paik KH; Jin DK
    Am J Med Genet A; 2012 Jan; 158A(1):90-6. PubMed ID: 22105882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcortical infarction in a young adult with Hunter syndrome.
    Kimura M; Azuma Y; Taguchi S; Takagi M; Mori H; Shimomura Y; Niwa JI; Doyu M; Okumura A
    Brain Dev; 2022 May; 44(5):343-346. PubMed ID: 35125232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment.
    Mohamed S; He QQ; Singh AA; Ferro V
    Adv Carbohydr Chem Biochem; 2020; 77():71-117. PubMed ID: 33004112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute airway obstruction in Hunter syndrome.
    Yoskovitch A; Tewfik TL; Brouillette RT; Schloss MD; Der Kaloustian VM
    Int J Pediatr Otorhinolaryngol; 1998 Aug; 44(3):273-8. PubMed ID: 9780074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelopathy in mucopolysaccharidosis type II (Hunter syndrome).
    Ballenger CE; Swift TR; Leshner RT; El Gammal TA; McDonald TF
    Ann Neurol; 1980 Apr; 7(4):382-5. PubMed ID: 6769383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of carpal tunnel syndrome in children with mucopolysaccharidosis type II (Hunter syndrome).
    Kwon JY; Ko K; Sohn YB; Kim SJ; Park SW; Kim SH; Cho SY; Jin DK
    Am J Med Genet A; 2011 Jun; 155A(6):1329-35. PubMed ID: 21567931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.